Highlights Allakos Inc.

Equities

ALLK

US01671P1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.1 ^USD	+7.84%		+3.77%	-59.71%

Mar. 15	North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	DJ
Mar. 14	Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Allakos Inc. Announces Publication Highlighting AK006 Mast Cell Inhibition	Feb. 12	CI
Allakos to stop further development of skin disease drug, plans job cuts	Jan. 16	RE
Allakos says experimental skin disease drug fails mid-stage studies	Jan. 16	RE
Allakos Announces Restructuring to Focus on Development of AK006	Jan. 16	CI
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints	Jan. 16	CI
Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Allakos Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-06	AQ
Allakos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-06	CI
Allakos Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-06	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-07	AQ
Allakos Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
Allakos Inc. Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria	22-09-12	CI
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis	22-09-09	CI
ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-04	AQ
Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
Allakos Q1 Loss Widens from Year Ago -- Stock Down Near 3% After-Hours	22-05-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Allakos Inc.

Equities

ALLK

US01671P1003

Highlights

Filters